In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Electro-Optical bags $11.5m funding:

This article was originally published in Clinica

Executive Summary

Manufacturer of the MelaFind non invasive melanoma diagnosis tool Electro-Optical Sciences (Irvington, New York) has secured $11.5m in a private placement from institutional investors. The funding, invested by Cowen and Company and ThinkEquity Partners, comprised just over 2 million common shares priced at $5.75 per share and around 500,00 common stock warrants that are exercisable at $8.00 for 54 months beginning six months after the closing of the investment. The company will use the proceeds to further the design and development of MelaFind, which emits multiple wavelengths to capture images of suspicious pigmented skin lesions, and extract data which can be analysed to tell physicians whether or not a lesion should be biopsied.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts